255 related articles for article (PubMed ID: 30318842)
21. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.
Abunahlah N; Sancar M; Dane F; Özyavuz MK
Int J Clin Pharm; 2016 Dec; 38(6):1464-1476. PubMed ID: 27796777
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
[TBL] [Abstract][Full Text] [Related]
24. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M; Molassiotis A; Dicato M; Peláez I; Rodríguez-Lescure Á; Pastorelli D; Ma L; Burke T; Gu A; Gascon P; Roila F;
Ann Oncol; 2012 Aug; 23(8):1986-1992. PubMed ID: 22396444
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
26. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
[TBL] [Abstract][Full Text] [Related]
27. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
[TBL] [Abstract][Full Text] [Related]
28. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Boccia R; O'Boyle E; Cooper W
BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
[TBL] [Abstract][Full Text] [Related]
30. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
[TBL] [Abstract][Full Text] [Related]
31. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.
Beauchemin M; Sung L; Hershman DL; Weng C; Dupuis LL; Schnall R
Support Care Cancer; 2020 Oct; 28(10):4761-4769. PubMed ID: 31974769
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
Clark-Snow R; Affronti ML; Rittenberg CN
Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.
Badarudin NS; Mohamed Shah N; Mohd Kassim KNB; Ismail F; Islahudin F; Mohd Tahir NA; Yusak S
Support Care Cancer; 2022 Jun; 30(6):5339-5349. PubMed ID: 35290510
[TBL] [Abstract][Full Text] [Related]
36. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.
Keefe DM; Chan A; Kim HK; Hsieh RK; Yu S; Wang Y; Nicholls RJ; Burke TA
Support Care Cancer; 2015 Jan; 23(1):253-61. PubMed ID: 25115893
[TBL] [Abstract][Full Text] [Related]
38. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
39. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
[TBL] [Abstract][Full Text] [Related]
40. Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy.
Iihara H; Fujii H; Yoshimi C; Yamada M; Suzuki A; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Int J Clin Oncol; 2016 Apr; 21(2):409-418. PubMed ID: 26475354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]